Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug-Reference-Cited by-同舟云学术

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug

Published:2018-10 Issue: Volume:136 Page:140-150
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Conklin Laurie S.,Damsker Jesse M.,Hoffman Eric P.,Jusko William J.,Mavroudis Panteleimon D.,Schwartz Benjamin D.,Mengle-Gaw Laurel J.,Smith Edward C.^ORCID,Mah Jean K.^ORCID,Guglieri Michela,Nevo Yoram,Kuntz Nancy,McDonald Craig M.^ORCID,Tulinius Mar,Ryan Monique M.,Webster Richard,Castro Diana^ORCID,Finkel Richard S.^ORCID,Smith Andrea L.,Morgenroth Lauren P.,Arrieta Adrienne,Shimony Maya,Jaros Mark,Shale Phil,McCall John M.,Hathout Yetrib,Nagaraju Kanneboyina,van den Anker John,Ward Leanne M.^ORCID,Ahmet Alexandra,Cornish Michaelyn R.,Clemens Paula R.

Funder

National Institutes of Health grant from the National Institute for Neurological Diseases and Stroke

National Institutes of Health grant from the National Institute for Arthritis and Musculoskeletal and Skin Diseases

National Institutes of Health grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development

Department of Defense

Muscular Dystrophy Association

Publisher

Elsevier BV

Subject

Pharmacology

Reference40 articles.

1. Early onset of inflammation and later involvement of TGFbeta in duchenne muscular dystrophy;Chen;Neurology,2005

2. Immune-mediated pathology in duchenne muscular dystrophy;Rosenberg;Sci. Transl. Med.,2015

3. CINRG investigators. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with duchenne muscular dystrophy: a prospective cohort study;McDonald;Lancet,2018

4. DMD care considerations working group. Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management;Birnkrant;Lancet Neurol.,2018

5. The time and determinants of first fractures in boys with duchenne muscular dystrophy;Ma;Osteoporos. Int.,2017

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review;Expert Opinion on Drug Safety;2024-08-27

2. Efficacy and safety of different doses of vamorolone in boys with Duchenne muscular dystrophy: a systematic review and network meta-analysis;Frontiers in Neurology;2024-08-21

3. Medical Statistics in Drug Development and Regulatory Approval;Advances in Bioinformatics and Biomedical Engineering;2024-07-18

4. Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials;Pharmacology & Therapeutics;2024-05

5. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy;The Journal of Clinical Pharmacology;2024-04-29